Sorafenib: clinical application and current status of multi-target anti-tumor drugs

Sorafenib is an oral multikinase inhibitor mainly used to treat advanced liver cancer, renal cell carcinoma and thyroid cancer. Its mechanism of action is to prolong patient survival by inhibiting tumor cell proliferation and angiogenesis. This article will focus on drug mechanism, indications, clinical effects and manufacturers to help readers fully understand the medical value and application scenarios of sorafenib.

Drug mechanism and core indications

Sorafenib blocks tumor growth and blood supply by targeting the RAF/MEK/ERK signaling pathway and tyrosine kinases such as VEGFR and PDGFR. In 2005, the US FDA first approved its use for advanced renal cell carcinoma, and later expanded to liver cancer (2007) and radioactive iodine-refractory thyroid cancer (2013). Clinical studies have shown that sorafenib can significantly prolong the median survival of patients with liver cancer (SHARP trial: 10.7 months vs placebo 7.9 months).

Clinical effects and adverse reaction management

In the key phase III trial, the disease control rate of patients in the sorafenib group was better than that of the control group, but common adverse reactions such as hand-foot syndrome, diarrhea, and hypertension require close monitoring. Physicians often recommend dose adjustment or combination of symptomatic treatments to improve tolerability. For example, urea ointment can be used topically for hand-foot syndrome, and patients with hypertension need to be combined with antihypertensive drugs.

Manufacturers and market status

The original drug was developed by the German company Bayer. After the patent expired, India and other countries have launched generic drugs. The price difference is significant. The annual treatment cost of the original drug is about US$50,000, while the cost of generic drugs can be reduced to 1/10.

Summary and Outlook

As the first approved systemic treatment drug for liver cancer, sorafenib has laid the foundation for targeted therapy. Although new generation drugs (such as lenvatinib) are gradually coming on the market, they are still core drugs on the medical insurance lists of some countries. In the future, combined treatment options need to be further optimized to improve patient survival benefits.

Quote sources:
1. FDA Drug Insert (Nexavar®)
2. "New England Journal of Medicine": SHARP trial (2008)
3. Product information on Bayer’s official website
4. World Health Organization International Clinical Trial Registration Platform